Midostaurin (PKC412)

Catalog No.S8064 Synonyms: CGP 41251

Midostaurin (PKC412) Chemical Structure

Molecular Weight(MW): 570.64

Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.

Size Price Stock Quantity  
USD 110 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.
Targets
PKCα [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKCβ2 [1]
(Cell-free assay)
PPK [1]
(Cell-free assay)
22 nM 24 nM 30 nM 31 nM 38 nM
In vitro

Midostaurin(pkc412) is a broad spectrum protein kinase inhibitor. Midostaurin(pkc412) interacts strongly with ATP binding sites of the conventional PKC-α, -β and -γ, PDGFRβ, VEGF-R2, VEGF-R1 and the cyclin-dependant kinase 1-cyclin B complex. Midostaurin(pkc412) inhibits the growth of various human and animal cell lines in vitro at similar submicromolar concentrations. Midostaurin(pkc412) also effectively inhibits the in vitro proliferation of glioblastoma and induced the accumulation of cells in G2/M and formation of giant nuclei with extensive fragmentation and apoptotic bodies. Midostaurin(pkc412) is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MV4-11 cells NYfGN5h1S3m2b4TvfIlkcXS7IHHzd4F6 NV3HSFR5PzJiaB?= M2nZTGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1XPC1zMTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[2WubDD0bZRmei2kbIXlJIF{e2G7LDDJR|UxRTF{IH7N MlHaNVk3PTR2MEi=
RS4-11 cells MonlSpVv[3Srb36gZZN{[Xl? MnfzNkBp M1e1S2lvcGmkaYTpc44hd2ZiRlzUN{BKXERibYX0ZY51KGG3dH;wbI9{eGixconsZZRqd25iaX6gbJVu[W5iUmO0MVEyKGOnbHzzJIFnfGW{IEKgbJJ{KGK7IHXs[YN1em:laHXtbYx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3ME2xN{BvVQ>? NVHteHFmOTl4NUS0NFg>
CGTH-W-1 cell NU\CfoZUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWfEZ2VYUW6qaXLpeIlwdiCxZjDoeY1idiCFR2TIMXcuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTR{Lk[1JO69VQ>? Mo\MV2FPT0WU
SW982 cell Mk\iS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUfTTlFWUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ2NjV6IN88US=> NHi0R2xUSU6JRWK=
human EoL-1-cell cell NYfrVZNtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUXJcohq[mm2aX;uJI9nKGi3bXHuJGVwVC1zLXPlcIwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Oi5yODDuUS=> Mkm4V2FPT0WU
MOLM-13 cells NVrSclZIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUixZoxEPzJiaB?= M32wZWlvcGmkaYTpc44hd2ZiRlzUN{BKXERiaHX0[ZJwgnmpb4XzJI12fGGwdDDpckBpfW2jbjDNU2xONTF|IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|IhcHK|IHL5JG1VWyCjc4PhfUwhT0l3ME2wMlA2PSEQvF2= MlHkNlYxQDFyMkO=
KASUMI-1 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXfBOo52UW6qaXLpeIlwdiCxZjDoeY1idiCNQWPVUWkuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwME[wNVYh|ryP M3Gxd3NCVkeHUh?=
NCI-H1755 cell NX7tN3RDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEjiZ3BKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVc2PSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwME[yO|Mh|ryP MVPTRW5ITVJ?
human MES-SA cell NGjGZpZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUnJcohq[mm2aX;uJI9nKGi3bXHuJG1GWy2VQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNFc2PDRizszN M{L0N3NCVkeHUh?=
human HCC1395 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHfkfotKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{GzPVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB6NEK4JO69VQ>? MYjTRW5ITVJ?
human D-336MG cell NF7qZoNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWP6dWFmUW6qaXLpeIlwdiCxZjDoeY1idiCGLUOzOm1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yOEe1OEDPxE1? MVjTRW5ITVJ?
CHP-212 cell NGmyUJlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWHBOZZ{UW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yOEe3N{DPxE1? NXrIPWZEW0GQR1XS
human KM12 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF\3[nhKdmirYnn0bY9vKG:oIHj1cYFvKEuPMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA6Ojd3IN88US=> M2\LZXNCVkeHUh?=
A204 cell NGXpfY1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFnCWIRKdmirYnn0bY9vKG:oIHj1cYFvKEF{MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlExODV{IN88US=> NIHDZ5lUSU6JRWK=
CAL-51 cell MnXnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2jNd2lvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yODdyOTFOwG0> MUXTRW5ITVJ?
human A431 cell M3TGRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4[wU2lvcGmkaYTpc44hd2ZiaIXtZY4hSTR|MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVEzOTZizszN MUfTRW5ITVJ?
NCI-H650 cell NEXye4ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M37wPGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2OVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjFzN{C4JO69VQ>? NGXwVJFUSU6JRWK=
A427 cell NEPJcpdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoXuTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNVkyQCEQvF2= M2TKTnNCVkeHUh?=
human 769-P cell NETwZ|dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFPoXo1KdmirYnn0bY9vKG:oIHj1cYFvKDd4OT3QJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOjB6MjFOwG0> MUjTRW5ITVJ?
SW1710 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoPZTY5pcWKrdHnvckBw\iCqdX3hckBUXzF5MUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE{OzF4IN88US=> MkXjV2FPT0WU
human H4 cell M{\EUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mnj4TY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUO5OlMh|ryP MVzTRW5ITVJ?
HT-1080 cell NYDOPVg4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVvJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTFyOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE2QTh{IN88US=> MWrTRW5ITVJ?
human PANC-03-27 cell Mm\kS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M33rbmlvcGmkaYTpc44hd2ZiaIXtZY4hWEGQQz2wN{0zPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMU[wNkDPxE1? Mke1V2FPT0WU
A375 cells MnTmR5l1d3SxeHnjbZR6KGG|c3H5 M4j5eVczKGh? Mo[yWI95cWOrdImgZYdicW6|dDDoeY1idiCDM{e1JINmdGy|IHHmeIVzKDd{IHjyd{BjgSClZXzsJJRqfGW{LXLseYUh[XO|YYmsJGlEPTB;MD6xPEDPxE1? MYWxPVY2PDRyOB?=
human HOP-62 cell MY\GeY5kfGmxbjDhd5NigQ>? NUfsc2liUW6qaXLpeIlwdiCxZjDoeY1idiCKT2CtOlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF6MEezJO69VQ>? MmruV2FPT0WU
human U031 cell MojCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml32TY5pcWKrdHnvckBw\iCqdX3hckBWODNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xPVY6QCEQvF2= M{XLO3NCVkeHUh?=
mouse BAF3 cells M2TtU3Bzd2yrZnXyZZRqd25iYYPzZZk> MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNidILhcpNnd3KvZXSge4l1cCCcTl[xPVguTkeIUkGgZ49ve3S{dXP0MEBKSzVyPUCuNkDPxE1? MXeyNVk{PjV2Mh?=
human G-402 cell M2\Lbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlHUTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlAzPTNizszN MYDTRW5ITVJ?
human G-361 cell NXO5bIh7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWnl[Wd5UW6qaXLpeIlwdiCxZjDoeY1idiCJLUO2NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjB6NUOg{txO NVfnS5FHW0GQR1XS
NCI-H810 cell M3n1WGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkPUTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEixNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjFyMkeg{txO NWDMSVIxW0GQR1XS
NCI-H2030 cell MkLYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoLUTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKwN|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|MEC2JO69VQ>? NVPHS5BoW0GQR1XS
human HCT-116 cell NGTUOJFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{XHNGlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUGxOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN3Nkig{txO NWD2[GVIW0GQR1XS
human SNU-423 cell M1TBW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmnWTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvNEKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOzZ3NzFOwG0> Mn3pV2FPT0WU
human SCC-4 cell M1\acGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVPJcohq[mm2aX;uJI9nKGi3bXHuJHNESy12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yN|k3PyEQvF2= NUTTPW5HW0GQR1XS
human SW48 cell NWnHT2dJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3;wfWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d2ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlY3QCEQvF2= MmDVV2FPT0WU
human SF295 cell M3TBeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUDPZVRRUW6qaXLpeIlwdiCxZjDoeY1idiCVRkK5OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjd{NUeg{txO NVX3TZJGW0GQR1XS
MDA-MB-231 cell M2TsTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4racGlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkixNFEh|ryP MVPTRW5ITVJ?
A172 cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXHoe|NiUW6qaXLpeIlwdiCxZjDoeY1idiCDMUeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zQTF3IN88US=> M1v6T3NCVkeHUh?=
human BCPAP cell MmDnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1rxeWlvcGmkaYTpc44hd2ZiaIXtZY4hSkOSQWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI6QDd7IN88US=> MkjpV2FPT0WU
human COLO-792 cell NV;TOlRIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVz1e|E4UW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVc6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkm5O|Ih|ryP M4LyVnNCVkeHUh?=
human DU-145 cell MljKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkX2TY5pcWKrdHnvckBw\iCqdX3hckBFXS1zNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMyQDh7IN88US=> NWrYXZFDW0GQR1XS
NCI-H2122 cell M2XnT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUDJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkGyNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ{OEWg{txO M{G5bnNCVkeHUh?=
human SK-UT-1 cell NInk[YhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIPvdHBKdmirYnn0bY9vKG:oIHj1cYFvKFONLWXUMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN{OUWyJO69VQ>? M4DtfnNCVkeHUh?=
LXF-289 cell M4rqOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHjQfolKdmirYnn0bY9vKG:oIHj1cYFvKEy[Rj2yPFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN{OU[1JO69VQ>? MUnTRW5ITVJ?
human NCI-H1792 cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NG\wcXNKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVc6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{OwPVYh|ryP MorhV2FPT0WU
MCF7 cell NI[zdYVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUXie5dKUW6qaXLpeIlwdiCxZjDoeY1idiCPQ1[3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzJ5NDFOwG0> M3v1RXNCVkeHUh?=
HCT-15 cell NX7GbYFmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUDJcohq[mm2aX;uJI9nKGi3bXHuJGhEXC1zNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|M1OzJizszN NV3vemxLW0GQR1XS
human NCI-H358 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH;u[JJKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IN|U5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|M{W1NUDPxE1? MUjTRW5ITVJ?
human HLE cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXHJcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{O3OVIh|ryP NWjJN3hIW0GQR1XS
human SW1088 cell M1;aR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NE\iTY9KdmirYnn0bY9vKG:oIHj1cYFvKFOZMUC4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN5OUeg{txO MlXpV2FPT0WU
human K5 cell NWjvT2FtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4T6W2lvcGmkaYTpc44hd2ZiaIXtZY4hUzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkO2NVQ6KM7:TR?= NUXueZFlW0GQR1XS
human SR cell NHXwN2lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3v5ZWlvcGmkaYTpc44hd2ZiaIXtZY4hW1JiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkO2OVcyKM7:TR?= MnPFV2FPT0WU
human Calu-3 cell Mn6yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoTETY5pcWKrdHnvckBw\iCqdX3hckBE[Wy3LUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM3QDJ3IN88US=> NF:3bFRUSU6JRWK=
human SK-MEL-30 cell NI\UN2tIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4ftfGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVMxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|OUmxN{DPxE1? NUTVfmRGW0GQR1XS
human SW780 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{\IOWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQyOTR{IN88US=> MWjTRW5ITVJ?
NCI-H1563 cell NIHvUWNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWjjVmVGUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE2PjNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkSxOFg1KM7:TR?= M3TqSXNCVkeHUh?=
human MKN45 cell NVTDSlFsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXLhb2c5UW6qaXLpeIlwdiCxZjDoeY1idiCPS160OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDF7M{Gg{txO M4S1bnNCVkeHUh?=
MDA-MB-157 cell M1fsWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYDacm5mUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOTV5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60NlAyPSEQvF2= MkTKV2FPT0WU
human NCI-H522 cell M1HSPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWHJNHp5UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUzOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNEKzJO69VQ>? NHfKT5FUSU6JRWK=
human A2780 cell NHfvOVFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGnR[4xKdmirYnn0bY9vKG:oIHj1cYFvKEF{N{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41PzVyMzFOwG0> MWTTRW5ITVJ?
human A498 cell M{HqT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml;oTY5pcWKrdHnvckBw\iCqdX3hckBCPDl6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60O|Y6OyEQvF2= Mo\lV2FPT0WU
human BxPC-3 cell M4jubWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGJ5WENvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFk{PjZizszN MYrTRW5ITVJ?
human A2058 cell MmPuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1H5XGlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlUzQDR2IN88US=> NHLrZ2xUSU6JRWK=
human PC-14 cell M1X0W2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3HNOGlvcGmkaYTpc44hd2ZiaIXtZY4hWENvMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU{QDV3IN88US=> NWfqTod5W0GQR1XS
human KG-1 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4X4dGlvcGmkaYTpc44hd2ZiaIXtZY4hU0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVU1OTlizszN MkjuV2FPT0WU
human A375 cell NEnGRWdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYLJcohq[mm2aX;uJI9nKGi3bXHuJGE{PzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkW2NVA{KM7:TR?= M3rmWXNCVkeHUh?=
human SW1783 cell Mny1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEC5[3RKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUe4N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzN|NzFOwG0> MWjTRW5ITVJ?
human MKN1 cell M4XqfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV;pSGg3UW6qaXLpeIlwdiCxZjDoeY1idiCPS16xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45QDRzMjFOwG0> NXPNS|dUW0GQR1XS
NCI-H1650 cell NYG5V3FGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWHxXXM6UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3PTBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLki4PVE364DCzszN NF\DWHVUSU6JRWK=
human HT-1376 cell M3foeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH;DdI9KdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGzO|Yh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjl{OUG4JO69VQ>? M2fDVXNCVkeHUh?=
SW872 cell M2jremdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHfzXFVKdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46PDR3OTFOwG0> MYnTRW5ITVJ?
human RT-112 cell NEXMfVNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFPzdYtKdmirYnn0bY9vKG:oIHj1cYFvKFKWLUGxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTd2OEOg{txO MWnTRW5ITVJ?
human HT-29 cell NUHxNJU{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4fiWGlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk4QTl4IN88US=> MnrpV2FPT0WU
human U-266 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4f4XWlvcGmkaYTpc44hd2ZiaIXtZY4hXS1{Nk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk5OzB{IN88US=> NXX4PYVpW0GQR1XS
human HEL cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUPJcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOUi1NVch|ryP NWnV[4xNW0GQR1XS
human KU812 cell MnfrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIDzS2xKdmirYnn0bY9vKG:oIHj1cYFvKEuXOEGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yOTF4NDFOwG0> Mlv4V2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Midostaurin(pkc412) may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addition to directly inhibiting tumor cell proliferation (via its effects on PKCs). This anti-angiogenic action may contribute to the antimetastatic and broad antitumor activity displayed by midostaurin(pkc412), as well as the synergy with cytotoxic agents, including doxorubicin, cyclophosphamide, cisplatin and gemcitabine. When given orally, the maximally tolerated dose for midostaurin(pkc412) is >300 mg/kg. [1]

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: A549, NCI-H520
  • Concentrations: ~1.0 μM
  • Incubation Time: 24-72 h
  • Method: Each well is added with 5 mM WST-1 and 0.2 mM 1-methoxy PMS and the absorbance at 450 nm is measured by a Microplate Reader.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Colo 205 colorectal tumors xenograft
  • Formulation: sterile water
  • Dosages: 50 mg/kg, 200 mg/kg, once daily
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (175.24 mM)
Ethanol 20 mg/mL warmed (35.04 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 570.64
Formula

C35H30N4O4

CAS No. 120685-11-2
Storage powder
in solvent
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01429337 Recruiting Hepatic Impairment Novartis Pharmaceuticals|Novartis March 7 2011 Phase 1
NCT03280030 Recruiting Acute Myeloid Leukemia Novartis Pharmaceuticals|Novartis April 6 2018 Phase 2
NCT02756962 Recruiting Acute Myeloid Leukemia Washington University School of Medicine|The Leukemia and Lymphoma Society July 6 2016 Phase 2
NCT01883362 Completed Acute Myeloid Leukemia Novartis Pharmaceuticals|Novartis February 6 2014 Phase 2
NCT02634827 Active not recruiting Acute Myeloid Leukemia With FLT3/ITD Mutation|Acute Myeloid Leukemia With Gene Mutations|FLT3 Tyrosine Kinase Domain Point Mutation|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia Mayo Clinic|National Cancer Institute (NCI) December 30 2015 Phase 2
NCT00045942 Completed Acute Myeloid Leukemia|Myelodysplastic Syndromes Novartis Pharmaceuticals|Novartis January 30 2002 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products0

Tags: buy Midostaurin (PKC412) | Midostaurin (PKC412) supplier | purchase Midostaurin (PKC412) | Midostaurin (PKC412) cost | Midostaurin (PKC412) manufacturer | order Midostaurin (PKC412) | Midostaurin (PKC412) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID